That’s the conclusion of the first study summarizing long-term outcomes from a series of prospective scientific trials of patients age group 60 and over who had been treated with the mini-transplant, a kinder, gentler type of allogeneic stem cell transplantation developed at Fred Hutchinson Cancers Research Center. The findings are published Nov. 2 in JAMA, The Journal of the American Medical Association. Age is no more a barrier to allogeneic transplant, stated Mohamed Sorror, M.D., M.Sc., an assistant member of the Hutchinson Center’s Clinical Analysis Division and corresponding author of the paper.And Figure 1). A complete of 11 patients died: 3 from cardiac causes, 2 each from sepsis and pulmonary infection, 2 from renal-cell carcinoma in the native kidneys, and 2 from unknown causes. The graft was still functioning at the time of death in 8 patients. Yet another 13 grafts failed owing to chronic rejection or chronic allograft nephropathy , vascular thrombosis , severe rejection , technical reasons , and nonadherence to medical therapy .